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Summary
Detailed characterization of the protective T-cell response in salmonellosis
is a pressing unmet need in light of the global burden of human Salmonella
infections and the likely contribution of CD4 T cells to immunity against
this intracellular infection. In previous studies screening patient sera against
antigen arrays, SseB was noteworthy as a serodominant target of adaptive
immunity, inducing significantly raised antibody responses in HIV-seroneg-
ative compared with seropositive patients. SseB is a secreted protein, part of
the Espa superfamily, localized to the bacterial surface and forming part of
the translocon of the type III secretion system (T3SS) encoded by Salmo-
nella pathogenicity island 2. We demonstrate here that SseB is also a target
of CD4 T-cell immunity, generating a substantial response after experimen-
tal infection in human volunteers, with around 01% of the peripheral rep-
ertoire responding to it. HLA-DR/peptide binding studies indicate that this
protein encompasses a number of peptides with ability to bind to several
different HLA-DR alleles. Of these, peptide 11 (p11) was shown in priming
of both HLA-DR1 and HLA-DR4 transgenic mice to contain an immuno-
dominant CD4 epitope. Analysis of responses in human donors showed
immunity focused on p11 and another epitope in peptide 2. The high fre-
quency of SseB-reactive CD4 T cells and the broad applicability to diverse
HLA genotypes coupled with previous observations of serodominance and
protective vaccination in mouse challenge experiments, make SseB a plausi-
ble candidate for next-generation Salmonella vaccines.
Keywords: CD4 epitope; HLA-DR transgenic; Salmonella; SseB; type 3
secretion system.
Introduction
There are estimated to be > 21 million cases of typhoid
fever annually. Salmonella infections cause outbreaks of
gastroenteritis in industrialized nations and enteric fever
and non-typhoidal Salmonella bacteraemia in resource-
poor regions of the world, killing over 600 000 people
annually.1 Disseminated non-typhoidal Salmonella infec-
tions are strongly associated with HIV infection and
young age in Asia and Africa.2,3 Since infection is food-
and water-borne, Salmonella infection is endemic in
regions where safe drinking water supply and adequate
sewage disposal are unavailable.
There are two widely licensed vaccines for typhoid,
but they offer only moderate protection and are not
widely used in endemic areas.4 The Vi polysaccharide
vaccine targets antibody to the capsule of Salmonella
Typhi, in a T-cell-independent response and therefore
lacks immunogenicity in children under 2 years old. The
live oral vaccine, Ty21a, requires three or four oral doses
for moderate efficacy and is not licensed for children
under 6 years of age. Protein–polysaccharide conjugate
vaccines for typhoid, again targeting antibody to the Vi
capsule, have recently been licensed in India and other
conjugated and live-attenuated vaccines are in develop-
ment,5,6 but there are no vaccines yet available to pre-
vent paratyphoid or non-typhoidal Salmonella infection
There is a considerable challenge posed by the need to
generate broad serovar coverage in a form that would be
suitable and effective for use in all susceptible individuals,
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including young infants, and would offer lasting immune
memory.
Many facets in the immune control of salmonellosis
remain poorly understood. There is evidence of the need
for T-cell and antibody-mediated control.7 In the case of
S. Typhi infection, up to 20% of infected individuals may
have recurring infection until a protective state is eventu-
ally attained, or they go on to relapse.8,9 There is only a
partial picture of the nature of CD4 T-cell immunity dur-
ing Salmonella infections and the identity of the key Sal-
monella T-cell antigens is unknown. Different phases of
host–pathogen interaction in the murine model of Salmo-
nella infection have been described.7 In the initial phase,
bacteria enter tissues, normally via the gut, then dissemi-
nate via the blood to the bone marrow, liver, spleen and
other tissues. Rapid bacterial growth is countered by
innate cytotoxicity, mainly through reactive oxygen inter-
mediates as well as antibody/complement-mediated
clearance. Once bacteria start to replicate intracellularly,
innate immunity remains important, for example,
through Nramp-1, as well as the linked activation of
adaptive immunity.7 Interferon-c (IFN-c) is probably
derived largely from natural killer cell activation initially,
and subsequently from T helper type 1 (Th1) cells,10 and
the importance of this pathway in defence is shown by
the preponderance of Salmonella infections among indi-
viduals with interleukin-12/IFN-c defects.11 During the
final phase, bacterial levels in tissues fall until clearance is
achieved. Adaptive T-cell immunity is seemingly not
required for initial control of infection as mice deficient
in CD4 cells, CD8 cells or both can control initial bacte-
rial growth.12 T-cell-mediated immunity is impaired in
the absence of B cells.13 Specific T-cell cytokine pro-
grammes have not been exhaustively mapped, but current
evidence suggests an important role for Th1 immunity.
McSorley’s group used tetramers loaded with epitopes
from Salmonella flagellin or from SseJ to track the pheno-
type of responding CD4 T cells during murine chal-
lenge.14 In line with the notion of Th1 predominance,
Tbet was the key CD4 transcription factor induced,
though there was skewing to Th17 responses among
flagellin-specific, gut CD4 T cells.14 Despite this being an
intracellular pathogen, mice lacking CD8 cells show
delayed bacterial clearance rather than substantially
enhanced disease susceptibility.15
There have been a limited number of studies aimed at
exploring candidates from the S. Typhi immunome for
serodiagnostic, serodominant or protective credentials with
respect to B-cell or T-cell immunity.16–19 Some candidate
antigens have been successfully deployed to induce protec-
tive immunity against challenge in mice; these antigens
include OmpL, SseB, SseD and CirA.16,18,19 Antigen arrays
have been informative: an array of 2724 Salmonella enterica
serovar Typhi antigens, selected on the basis of key terms
such as ‘outer membrane’ or ‘chaperone’, representing
over 63% of the proteome was screened for responses in
immune sera from mice infected with Salmonella
Typhimurium BRD509.18 A total of 117 antigens were
detected, some of these differentially between the different
resistant or susceptible mouse strains used. Studies with
patient sera identified 16 seroreactive antigens differentially
bound by sera from patients with acute typhoid and
healthy controls.18 Fourteen of these antigens were
detected in sera from Malawian paediatric acute cases and
SseB was noteworthy as a target of adaptive immunity,
inducing significantly raised antibody responses in HIV-
seronegative compared with HIV-seropositive subjects. In
studies on protection of C57BL/6 mice from oral challenge
with Salmonella SL1344, immunization with two doses of
SseB offered substantial protection with respect to mean
survival time and tissue bacterial burden.18
SseB is a secreted protein, part of the Espa superfamily,
localized to the bacterial surface and forming part of the
translocon of the type III secretion system
(T3SS) encoded by the Salmonella pathogenicity island 2
(Spi2).19 The other components include SseC and SseD.
The T3SS of Salmonella is induced during the intracellu-
lar phase of infection when bacteria are found in the Sal-
monella-containing vacuole and must be able to
translocate effector proteins across the host cell plasma
membrane.20,21 The role of SseB is to promote membrane
pore formation, allowing proteins to access host cyto-
plasm: SseB mutant strains lack the ability to translocate
SPI2 effector proteins during intracellular infection of
macrophages.22
The EspA protein of enteropathogenic Escherichia coli
(EPEC), which is an orthologue of Salmonella SseB, has
been evaluated as a protective vaccine candidate in
EPEC.23 In seeking to further establish the credentials of
SseB as a Salmonella vaccine candidate antigen, we here
set out to validate the credentials of SseB as a target of
CD4 immunity in the context of Salmonella infection and
determine the impact of HLA class II polymorphisms on
immune recognition of immunodominant epitopes.
Materials and methods
SseB protein and peptide panel
Recombinant SseB protein was produced and purified
after codon optimization and sub-cloning into the vector
pBMH for expression in E. coli (Biomatik, Wilmington,
DE). An SseB peptide library comprising 20-mers over-
lapping by 10 amino acids was synthesized by GL Bio-
chem (Shanghai) Ltd (Shanghai, China; Table 1).
HLA-transgenic mice
Mice transgenic for HLA-DR1 (that is, HLA-
DRA1*0101/HLA-DRB1*0101) and HLA-DR4 (that is,
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HLA-DRA1*0101/HLA-DRB1*0401)24–26 were bred and
housed in the Centre for Biological Services at the Ham-
mersmith campus, Imperial College London, UK, in
accordance with Home Office regulations and College
ethics review. Both transgenic lines are maintained on a
C57BL/6 background as homozygotes for knockout of
murine MHC Class II H2-Ab.27
Human peripheral blood mononuclear cells donors
CD4 T cell responses to SseB were analysed in peripheral
blood mononuclear cell (PBMC) samples from healthy
control donors with no reported clinical history of Salmo-
nella infection and from donors who had been experi-
mentally challenged with S. Typhi 12 months previously
as described elsewhere.28 Healthy control blood samples
were collected with informed consent, under the approval
of Ethics REC reference number 08/H0707/173. The
S. Typhi challenge participants were recruited by
the Oxford Vaccine Group, University of Oxford and the
study was performed at the Centre for Clinical Vaccinolo-
gy and Tropical Medicine, Oxford. Ethics approval was
obtained from the NRES Committee South Cen-
tral – Oxford A (11/SC/0302). Written, informed consent
was provided by all participants. A pre-determined bacte-
rial dose (104 colony-forming units) of challenge agent
(Quailes strain) was delivered by oral ingestion suspended
in a sodium bicarbonate solution.28 Study exclusion crite-
ria included previous typhoid vaccination, residence in a
typhoid endemic country for over 6 months and known
diagnosis of a probably or confirmed typhoid infection.
Blood samples were collected and PBMCs were purified
by Lymphoprep density gradient separation.
Human IFN-c ELISpot
Human IFN-c ELISpot assays were run using reagents
from Mabtech (Stockholm, Sweden). Briefly, 2 9 105
thawed PBMCs were incubated in pre-coated human IFN-
c ELISpot plates, in triplicate, with 50 lg/ml of SseB pep-
tide or recombinant protein (25 lg/ml) in RPMI-1640
medium containing 2 mM L-glutamine, 50 U/ml penicillin
G, 50 lg/ml streptomycin sulphate and 10% fetal calf
serum. Cells were cultured at 37° and in 5% CO2 for
24 hr before assay development using an horseradish
peroxidase-labelled detection antibody and Tetramethyl-
benzidine (TMB) substrate. Developed plates were left to
dry before spot counting using an AID ELISpot reader
(Autoimmun Diagnostika GMBH, Straßberg, Germany).
Positive epitopes for a given individual were defined as a
greater number of spot-forming cells than 2 SD over the
mean of the no protein/peptide control triplicate. To
better define HLA restriction, human donor ELISpot
responses were also analysed in the presence of HLA class
II blocking monoclonal antibodies at a final concentration
of 25 lg/ml: L243 (anti-HLA-DRa), SPVL-3 (anti-HLA-
DQ), B7/21 (anti-HLA-DP) and control mouse IgG.
Murine IFN-c ELISpot
HLA-DR1 or HLA-DR4 transgenic mice were primed, by
subcutaneous injection into the footpad, with 25 lg
of recombinant SseB protein administered as a 1 : 1
emulsion with TiterMax Gold (CytRx Corporation, Los
Angeles, CA). Ten days after priming, popliteal draining
lymph nodes were harvested and stimulated, in triplicate,
at 2 9 105 cells per well with 25 lg of SseB peptide or
recombinant protein in pre-coated murine IFN-c ELISpot
plates (2BScientific, Upper Heyford, Oxfordshire, UK).
Culture medium was RPMI-1640 containing 2 mM L-glu-
tamine, 50 U/ml penicillin G, 50 lg/ml streptomycin sul-
phate, 50 lM b-mercaptoethanol and 10% fetal calf
serum. Cells were cultured at 37° and in 5% CO2 for
72 hr before assay development using a biotinylated anti-
IFN-c antibody, a horseradish peroxidase detection anti-
body and TMB substrate (2BScientific). Developed plates
were left to dry before spot counting using an AID ELI-
Spot reader (Autoimmun Diagnostika GMBH). Positive
epitopes for a given transgenic line were defined as those
where more than half of assayed animals gave a greater
number of spot-forming cells than 2 SD over the mean of
the no protein/peptide control.
Peptide/HLA-DR binding assays
HLA-DR heterodimers were purified from homozygous
Epstein–Barr virus B-lymphoblastoid cell lines (HPA
Table 1. Amino acid sequences of 18 overlapping SseB peptides used
for HLA binding, HLA transgenic and human epitope mapping
studies. Peptides are 20 amino acids in length and adjacent peptides
overlap by 10 amino acids
Peptide Peptide name Amino acid sequence
1 T1266 [1–20] MSSGNILWGSQNPIVFKNSF
2 T1266 [11–30] QNPIVFKNSFGVSNADTGSQ
3 T1266 [21–40] GVSNADTGSQDDLSQQNPFA
4 T1266 [31–50] DDLSQQNPFAEGYGVLLILL
5 T1266 [41–60] EGYGVLLILLMVIQAIANNK
6 T1266 [51–70] MVIQAIANNKFIEVQKNAER
7 T1266 [61–80] FIEVQKNAERARNTQEKSNE
8 T1266 [71–90] ARNTQEKSNEMDEVIAKAAK
9 T1266 [81–100] MDEVIAKAAKGDAKTKEEVP
10 T1266 [91–110] GDAKTKEEVPEDVIKYMRDN
11 T1266 [101–120] EDVIKYMRDNGILIDGMTID
12 T1266 [111–130] GILIDGMTIDDYMAKYGDHG
13 T1266 [121–140] DYMAKYGDHGKLDKGGLQAI
14 T1266 [131–150] KLDKGGLQAIKAALDNDANR
15 T1266 [141–160] KAALDNDANRNTDLMSQGQI
16 T1266 [151–170] NTDLMSQGQITIQKMSQELN
17 T1266 [161–180] TIQKMSQELNAVLTQLTGLI
18 T1266 [171–196] AVLTQLTGLISKWGEISSMIAQKTYS
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Culture Collections, Salisbury, UK) by affinity chroma-
tography with the monomorphic HLA-DRa monoclonal
antibody, L243.29,30 Binding of the SseB peptide panel to
the HLA-DR molecules HLA-DRB1*01:01, 03:01, 04:01,
07:01, 09:01, 11:01, 12:02, 15:01, 15:02 was assessed by
competitive ELISA, as previously described, using an
automated workstation.29,30 We evaluated the peptide
concentration able to prevent binding of 50% of the
labelled peptide (IC50). Data were expressed as relative
affinity: ratio of the IC50 of the peptide to the IC50 of the
reference peptide, which is a high binder to the HLA class
II molecule. Unlabelled forms of the biotinylated peptides
were used as reference peptides. Their sequences and IC50
values were the following: HA 306–318 (PKYVKQNTLK-
LAT) for DRB1*01:01 (2 nM), DRB1*04:01 (69 nM),
DRB1*07:01 (30 nM) and DRB1*1101 (36 nM), MT2-16
(AAKTIAYDEEARRGLE) for DRB1*03 :01 (84 nM), CTP
427–441 (VHGFYNPAVSRIVEA) for DRB1*0901
(15 nM), TFR 141–155 (TGTIKLLNENSYVPR; 73 nM) for
DRB1*1202, A3 152–166 (EAEQLRAYLDGTGVE) for
DRB1*15:01 (37 nM) and TFR 607–620 (LNLDYER-
YNSQLLS) for DRB1*15:02 (3 nM).
Results
The SseB sequence encompasses peptides with broad
binding to multiple HLA-DR alleles
The HLA-DR peptide-binding assay used here
was designed to give a strong coverage of commonly
expressed alleles across diverse populations. For example,
the DR1, 3, 4, 7, 11 and 1501 heterodimers cumulatively
cover approximately 80% of individuals in Caucasian
populations, whereas DR9, DR1202 and DR1502 are rare
in Caucasian populations but are found in around a third
of individuals in many South East Asian populations. Of
the 18 peptides encompassing the SseB overlapping pep-
tide library, 15 show significant HLA-DR binding
(Table 2). Eight peptides were able to bind specifically to
only one or two alleles, but the seven other binders were
able to bind more heterodimers. It is noteworthy that
there are three peptides, p2, p11 and p18, with the prop-
erty of binding 6, 7 and 8 different HLA-DR heterodi-
mers, respectively. They span HLA-DRB sequences with
rather diverse peptide-binding pockets.
Mapping immunodominant SseB epitopes in HLA-DR
transgenic mice
There are clear logistical problems inherent in the eluci-
dation of patterns of HLA class II restriction in outbred
human populations: a CD4 T-cell response to a given
peptide may result from presentation through any one of
the several different class II heterodimer species expressed
on each antigen-presenting cell. We have therefore
favoured the approach of complementing analysis of
human donor responses with analysis in immunized HLA
transgenics.24–26,30 HLA-DR1 and HLA-DR4 transgenic
lines, each also carrying a homozygous deletion for endog-
enous murine H2-Ab, were immunized with recombinant
SseB protein (Fig. 1a,b). Ten days later, recall responses
were tested by IFN-c ELIspot of popliteal lymph node T
cells. Immunization of HLA-DR1 transgenics shows that
whole SseB protein is highly immunogenic in this strain
and that p2, p11 and p18 peptides carry HLA-DR1
restricted immunodominant CD4 epitopes (Fig. 1a). In
HLA-DR4 transgenics, there is again a relatively large
response to the whole SseB protein, with CD4 epitopes
detected in p11 and p14 (Fig. 1b). Hence, p11, which
binds with moderate to high affinity to the seven HLA-
DR heterodimers screened, is shown to be functionally
relevant to the HLA-DR1 and -DR4 CD4 T-cell reper-
toire. Peptide 18, which can bind to both DR1 and DR4,
was found to contain a functional CD4 epitope in the
context of DR1 but not DR4.
Human CD4 T-cell epitopes from SseB
We then analysed human CD4 T-cell IFN-c ELIspot
responses to SseB and the SseB peptide library. Two
human cohorts were used, one comprising donors who
had 12 months previously been challenged with 104 col-
ony-forming units of live S. Typhi strain and the other
comprising healthy volunteers with no known specific
clinical history of Salmonella-related illness (Fig. 2a,b).
Response of a given individual to a particular peptide
from the SseB library was defined as positive if the num-
ber of spot-forming cells was > 2 SD above the mean of
the no-peptide/protein control for that individual. Partic-
ularly noteworthy in this analysis is that cells from both
cohorts show a very sizeable T-cell response to whole
SseB protein, approaching 1 in a 1000 of the peripheral
repertoire; this suggests that the adaptive immune system
was significantly exposed to Salmonella SseB (or its cross-
reactive orthologues in related pathogens) and devotes a
sizeable immune repertoire to its recognition. All of the
individuals screened across the two cohorts respond to
whole SseB and to at least some of the peptides. Across
both cohorts, the largest and most common peptide
responses are to p2 and p11, the key epitope predicted by
the HLA transgenic mouse screen. However, p18, which
had been identified as a peptide with broad HLA-DR
binding and as an epitope in HLA-DR1 transgenics but
not in HLA-DR4 transgenics, is less frequent among the
epitopes recognized by the human donor cells. Two of
the four challenged donors became clinically unwell with
typhoid and two did not; the former pair were character-
ized by a narrower CD4 response focused on p2 and p11,
while the latter pair mounted a response to a larger num-
ber of epitopes.
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All of the donors for this study were HLA genotyped
(Table 3), but no particular HLA class II alleles were
identified that correlated with patterns of response,
including p2 and p11 recognition. Attempts were made
to use HLA class II monoclonal antibody blocking studies
of bulk responses for imputing dominant HLA restriction
of responses; due to consequences of cross-linking
between class II molecules, these studies can, in our expe-
Table 2. Relative binding of SseB peptides to HLA-DR heterodimers
Peptide CD4 T-cell epitope
Relative binding affinity of peptide to HLA-DR molecules1
DRB1
*0101
DRB1
*0301
DRB1
*0401
DRB1
*0701
DRB1
*0901
DRB1
*1101
DRB1
*1202
DRB1
*1501
DRB1
*1502
1 1MSSGNILWGSQNPIVFKNSF20 447 > 119 12 6 > 689 > 278 3 7 > 3 333
2 11QNPIVFKNSFGVSNADTGSQ30 300 > 119 9 14 10 > 278 59 04 5
3 21GVSNADTGSQDDLSQQNPFA40 > 4149 > 119 > 145 > 336 > 689 ND > 136 > 270 > 3 333
4 31DDLSQQNPFAEGYGVLLILL50 22 > 119 > 145 6 28 ND > 136 10 55
5 41EGYGVLLILLMVIQAIANNK60 > 4149 > 119 > 145 > 336 > 689 > 278 > 136 > 270 > 3 333
6 51MVIQAIANNKFIEVQKNAER70 235 > 119 6 2 > 689 8 2 1 577
7 61FIEVQKNAERARNTQEKSNE80 4500 89 109 > 336 > 689 > 278 > 136 211 > 3 333
8 71ARNTQEKSNEMDEVIAKAAK90 > 4149 > 119 > 145 > 336 > 689 > 278 > 136 > 270 > 3 333
9 81MDEVIAKAAKGDAKTKEEVP100 1508 41 > 145 > 336 626 8 > 136 200 > 3 333
10 91GDAKTKEEVPEDVIKYMRDN110 > 4149 > 119 > 145 87 > 689 > 278 > 136 58 > 3 333
11 101EDVIKYMRDNGILIDGMTID120 61 > 119 17 2 34 > 278 8 03 37
12 111GILIDGMTIDDYMAKYGDHG130 > 4149 18 > 145 167 > 689 > 278 105 12 1 826
13 121DYMAKYGDHGKLDKGGLQAI140 2958 > 119 > 145 > 336 > 689 > 278 > 136 12 2 000
14 131KLDKGGLQAIKAALDNDANR150 335 > 119 13 17 50 > 278 71 10 > 3 333
15 141KAALDNDANRNTDLMSQGQI160 > 4149 57 > 145 > 336 > 689 > 278 > 136 > 270 > 3 333
16 151NTDLMSQGQITIQKMSQELN170 964 > 119 > 145 > 336 > 689 > 278 52 > 270 > 3 333
17 161TIQKMSQELNAVLTQLTGLI180 18 > 119 > 145 8 > 689 > 278 > 136 > 270 > 3 333
18 171AVLTQLTGLISKWGEISSMIAQKTYS196 2 > 119 2 12 21 7 4 05 63
1Results are expressed as a relative binding ratio obtained by dividing the IC50 of peptide by that of a reference peptide that binds strongly to the
HLA molecule. Lower numbers correspond to a higher binding affinity. Numbers in bold with a ratio of 20 or less = high affinity binding; num-
ber in bold with a ratio of 20–100 = moderate affinity binding. Each peptide–MHC combination was evaluated in three independent experi-
ments.
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Figure 1. Definition of HLA-DR specific T-cell
epitopes in DR1 and DR4 transgenic mice. (a)
HLA-DR1 (n = 5) and (b) HLA-DR4 (n = 6)
mice were footpad primed with ssEB protein
in combination with TiterMax Gold adjuvant.
Draining lymph node (DLN) cells were assayed
by ELISpot at day 10 for interferon-c (IFN-c)
T-cell responses to ssEB peptides and protein.
A peptide was defined as containing a T-cell
epitope for DR1 or DR4 HLA molecules if
more than half of the mice assayed gave a
greater number of spot-forming cells than 2
SD over the mean of the no peptide/protein
control. The 2 SD value for each transgenic
line is shown by a dotted line.
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rience, as often show enhancement of functional responses
as blocking. We nevertheless undertook extensive addi-
tional studies of this type in an attempt to illuminate the
nature of p2 and p11. While anti-DR blocking studies
(with L243) indeed tended to show enhancement of
responses (data not shown), we identified clear and spe-
cific inhibition by the anti-DQ monoclonal antibody,
SPVL-3 in the p11 response of donor EC02 (see Support-
ing information, Fig. S1). This suggests that the very
broad responses to these immunodominant epitopes may
result in part from the ability to be presented both by
HLA-DR and HLA-DQ isotypes.
Variation in the SseB p11 epitope across Salmonella
enterica serovars
In light of the immunoprevalence of the SseB p11 epitope
as determined across HLA polymorphisms in both trans-
genic mice and in humans, it was important to determine
the extent to which this epitope might vary across
enterica serovars (Fig. 3). Positions 1, 5, 9 and 10 within
the 20-mer p11 are variable across S. enterica strains, pos-
sibly arguing for selection driven by host T-cell immu-
nity. The epitope is to a degree conserved in more
distantly related species than members of the Espa super-
family, such as Yokenella and Vibrio sp.
Discussion
There has been relatively little functional and immunoge-
netic dissection of CD4 T-cell immunity to Salmonella in
the context of human infection. Studies on human live-
attenuated vaccine volunteers at the Center for Vaccine
Development (University of Maryland) show that specific
responses encompass both IFN-c and interleukin-17 from
polyfunctional T cells, with CD4 and CD8 responses both
induced.31 Sheikh et al.32 used S. Typhi membrane prepa-
ration proteins to analyse the IFN-c ELIspot responses of
acute or convalescent typhoid patients in Bangla-
desh. Seven different antigens were studied, strong CD4
responses being observed in acute and convalescent
patient samples in response to StaF, CsgF, PagC, StbB,
CdgD, OppA and STY2195. A recent study characterized
CD4 and CD8 responses in C57BL/6 mice following oral
challenge with live S. Typhimurium.33 Predictive algo-
rithms were used to select some 1400 predicted antigenic
epitopes, conserved across Typhi and Typhimurium
sequences, yielding clear responses to the alkyl hydroper-
oxide reductase subunit C (AhpC), the ethanolamine
ammonia-lyase small subunit (EutC) and in STM1540, a
putative hydrolase. The AhpC epitope was of particular
interest, being highly conserved across several other
pathogens including Pseudomonas, Burkholderia and
Citrobacter sp. However, prophylactic vaccination with
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Figure 2. T-cell responses to peptides of ssEB,
particularly peptides 2 and 11, are detectable
in peripheral blood mononuclear (PBMC)
samples from Salmonella-exposed individuals.
Peripheral blood samples (PBMC) (a) Salmo-
nella exposed (n = 4) and (b) healthy control
(n = 6) individuals were assayed by ELISpot
for IFN-c T-cell responses to SseB peptides
and protein. Response of a given individual to
a particular peptide was defined as positive if
the number of spot-forming cells was > 2 SD
over the mean of the no peptide/protein con-
trol for that individual. Responses not defined
as positive are plotted as zero. Mean spot-
forming cells per 106 PBMC for each group is
represented by a straight line.
Table 3. HLA class II genotypes of donors for this study
Subject
HLA class II
DRB1 DQB1
HC01 1 103 5 5
HC02 1 13 5 6
HC03 1 17 2 5
HC04 13 13 6 7
EC01 15 7 2 6
EC02 1 15 5 6
EC03 4 13 6 8
EC04 17 4 2 8
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the immunodominant CD4 epitopes did not significantly
enhance bacterial clearance.33
Serodominant antigens picked up as targets through
screening of patient sera often contain strong CD4 T-cell
epitopes. We here investigated whether, SseB, a compo-
nent of the Salmonella T3SS and found to be strongly
seroreactive in analysis of both infected mice and a Mal-
awian paediatric cohort18 was strongly recognized by CD4
T cells as well. A key finding is that there is a very high
frequency of SseB-specific CD4 T cells, whether in immu-
nized HLA-DR transgenics, donors who have been
through a live S. Typhi challenge protocol or indeed in
healthy controls. The very substantial response in the
human donors, around 01% of the repertoire, argues
either that individuals can be strongly primed asymptom-
atically through repeated exposure to food-borne Salmo-
nella, or that, because SseB is a member of the relatively
conserved Espa superfamily of bacterial T3SS proteins,
there is a degree of ongoing, cross-reactive immune stim-
ulation through epitopes from, for example, Vibrio spe-
cies (Figure 3). We found amino acid residues 1, 5, 9 and
10 within p11 to be variable across S. enterica strains,
which may be compatible with the notion of selection
driven by adaptive immunity, although the sequence is
conserved across typhoid and paratyphoid sequences.
While our binding studies show p11 to be a rather pro-
miscuous binder, able to bind with moderate or high
affinity to several HLA-DR alleles, predictive algorithms
such as NetMHCII suggest that this range of binding
would not extend also to presentation by HLA-DQ hete-
rodimers. NetMHCII predicts a core binding sequence of
YMRDNGIL for HLA-DR1 and of IKYMRDNGILI for
HLA-DR15. Hence, the variability between S. enterica ser-
ovars at amino acid 1 of p11 where there is an E/D
switch between variants is likely to be irrelevant to HLA
class II binding and T-cell receptor recognition. The tyro-
sine is predicted, for HLA-DR alleles including DR1,
DR4, DR9 and DR1502, to sit in pocket 1 with the vari-
able, albeit conservative, D/E in pocket 4, and so probably
to impact on differential interactions with HLA-DR hete-
rodimers. The N/H dimorphism at P5 is predicted to lie
at the key T-cell receptor contact residue, and so the dif-
ference is highly likely to impact on T-cell activation. A
second binding register seems to be shared by HLA-DR7
and HLA-DR1501 and uses the I in position 4 as a P1
anchor residue. D/E and H/N dimorphisms affect the sec-
ondary P6 and P7 anchor residues and would be expected
to lead to differential binding activities. Finally, V in posi-
tion 3 serves as a P1 residue for the DR1202 allotype
only. In this binding mode, only D/E affects an HLA-
binding residue while H/N and K/I are expected to point
to the T-cell receptor. The p11 peptide elicits strong
CD4 immunity and, remarkably, is commonly recognized
across diverse human donors and HLA transgenic mice,
related to its capacity to bind to multiple HLA-DR mole-
cules. Blocking studies with the HLA-DQ monoclonal
antibody, SPVL-3, suggest that a component of the
response to p11 can be HLA-DQ restricted, which may
further contribute to immunodominance. By contrast, the
p18 peptide is a more promiscuous binder than the p11
peptide, although it is less frequently recognized by
T cells. Several studies affirm that the number of memory
antigen-specific T cells depends on the number of anti-
gen-specific naive cells at the initiation of the response34–
36 and in particularly, discriminate peptides with similar
binding activity but differential T-cell-activating proper-
ties.37
SseB is one of many secretion system components that
appear to feature strongly in the T-cell immunome of
diverse bacterial infections including Salmonella, Mycobac-
terium tuberculosis and Burkholderia; perhaps the key
example in this respect is ESAT-6 (EsxA), a part of the
mycobacterial type VII secretion system.38
Although it is generally accepted that T cells play an
important role in limiting Salmonella infections, the phe-
notype, specificity and location of these responses in
humans remains unknown. The finding of strong SseB
responses pre-existing in healthy controls, who have not
EDVIKYMRDNGILIDGMTID Salmonella enterica, subsp enterica serovar Typhi str Ty2 SseB
EDVIKYMRDNGILIDGMTID Salmonella typhimurium (strain ATCC 68169 / UK-1), SseB
EDVIKYMRDNGILIDGMTID Salmonella Paratyphi A (strain ATCC 9150 / SARB42),SseB
DDVIKYMRDHGILIDGLTID Salmonella enterica subsp. enterica serovar Paratyphi B str. SPB7, SseB
EDVIKYMRDHGILIDGMTID Salmonella enterica subsp. serovar Arizona, SseB
DDVIKYMRDHGILIDGMTID Salmonella enterica subsp. enterica serovar Montevideo, SseB
DDVIKYMRDHGILIDGMTID Salmonella enterica subsp. enterica serovar Javiana, SseB
EDVIIYMREHGILIDGMTID Salmonella enterica subsp. enterica serovar Adelaide, SseB
DDVIIYMREHGILIDGMTID Salmonella enterica subsp. enterica serovar Chester, SseB 
EDVIIYMREHGILIDGLTID Salmonella enterica subsp. enterica serovar Cubana, SseB
DEVVKYMRDNGILVDGMSID  Yokenella regensburgei, EspA secretion protein
DDVVKYMHDNGFTIDGMTID Shewanella baltica, EspA secreted protein
DVLKYMKDNN ILVNGKTID  Burkholderia oklahomensis, EspA secretion protein 
EVINYMRDN GFTVDGKTID  Vibrio coralliilyticus, EspA secretion protein
QDVIDYMKKNNILVAGKNID Gamma proteobacterium, hypothetical protein
Figure 3. Conservation of the p11 T-cell epitope across Salmonella and other bacterial species. Conserved residues across Salmonella clades are
shown in yellow, variant residues in turquoise.
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had invasive Salmonella infections, suggests that these
responses may be generated at the mucosa as a result of
universal exposure to orthologous sequences derived from
other pathogens and the bacteria of the human microbi-
ota. This finding means that it is likely that such pre-
existing responses are present among those who go on to
develop typhoid after exposure, and that SseB immunity
may therefore be insufficient to confer resistance to inva-
sive Salmonella infections. On the basis of the current
study and in the absence of CD45RA/RO flow cytometric
assays, we also cannot formally exclude the possibility
that a component of the very sizeable response to SseB
may be contributed by priming of a response in naive
cells. However, our observations are consistent with the
role for SseB immunity shown in limiting infection dur-
ing invasive salmonellosis as shown in the C57BL/6 pro-
tection studies with Salmonella SL134.18 Further studies
are required to relate the magnitude of responses to
attack rate in experimental challenge and duration and
severity of infection.
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Figure S1. Specific blocking of the response to p11 in
donor EC02 by anti-HLA-DQ monoclonal antibody SPVL-
3 added to cultures at 25 µg/ml.
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